Since the introduction of regulatory drug approval guidance on the evaluation of QT interval prolongation, an increasing number of drug monographs has included cautions on the risk of QT prolongation. For example, QT prolongation is mentioned in the Canadian product monographs of 29 drugs commonly seen in oncology practice. This presents two major challenges. First, most guidelines and risk predictive tools for QT prolongation have been developed for hospitalized patients in acute care settings. In contrast, most QT-prolonging oncology drugs are used in medically stable patients in the ambulatory setting. Second, many oncology drugs are unique for their indications and non-QT prolonging alternative agents are often not available. In this review, we will outline an empiric initial approach to ambulatory cancer patients who are treated with oncology drugs which may prolong QT interval. This includes the predictive value of QT prolongation on torsades de pointes, the risk factors of the patients and the drugs, and the limitations of existing guidance in this area.
Group ICHEW. ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.
2.
Group ICHEW. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14). Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.
3.
DrewBJAckermanMJFunkMet al.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation2010; 121: 1047–1060.
4.
TisdaleJEJaynesHAKingeryJRet al.Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes2013; 6: 479–487.
5.
BrellJM. Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis2010; 53: 164–172.
6.
TamargoJCaballeroRDelponE. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf2015; 38: 129–152.
7.
Åström-LiljaCOdebergJMEkmanEet al.Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidem Drug Saf2008; 17: 587–592.
8.
ShafferDSingerSKorvickJet al.Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis2002; 35: 197–200.
9.
ChouRCrucianiRAFiellinDAet al.Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain2014; 15: 321–337.
10.
ZeltserDJustoDHalkinAet al.Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine2003; 82: 282–290.
11.
Woosley RL and Romero KA. QT drugs List 1822 Innovation Park Dr., Oro Valley, AZ 85755: AZCERT Inc., www.Crediblemeds.org (accessed 22 December 2016).
12.
PostemaPGNevilleJde JongJSSGet al.Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace2013; 15: 1042–1049.
TrumpDLSmithDCEllisPGet al.High-Dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst1992; 84: 1811–1816.
16.
PollackIFDaRossoRCRobertsonPLet al.A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res1997; 3: 1109–1115.
17.
Pharmacovigilance Risk Assessment C. PRAC recommendations on signals, London, United Kingdom: European Medicines Agency, 2014, pp. 240–253.
18.
GarnickMBPrattCMCampionMet al.The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. Urology2004; 22(14S (15 Suppl)): 4578–4578.
19.
SmithMRKlotzLPerssonBEet al.Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol2010; 184: 2313–2319.
MasonJWSelnessDSMoonTEet al.Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res2012; 18: 2913–2221.
Anon. QT interval and drug therapy. BMJ2016; 353: i2732–i2732.
25.
Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006; 47: 362–367.
26.
EarlNCrawfordJSmithWet al.Community detection of long QT syndrome with a clinical registry: an alternative to ECG screening programs?Heart Rhythm2013; 10: 233–238.
27.
TrinkleyKEPageRL2ndLienHet al.QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin2013; 29: 1719–1726.
